Bio-Thera Solutions (SHA:688177) received marketing approval from Singapore's Health Sciences Authority for ustekinumab biosimilar BAT2206.
The drug is indicated for psoriasis and Crohn's disease in children and adults, according to a Thursday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% in recent trade.